Axcella Therapeutics (AXLA)
Phase 2a Data In Long COVID-19 Shows Improvements In Fatigue and Function
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to restore cellular homeostasis in multiple key biological pathways and improve cellular energetic efficiency. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and non-alcoholic steatohepatitis (NASH), and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.
Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Phase 2a Trial In Long COVID-19 Shows Benefits. Accella announced preliminary results from its Phase 2a trial testing AXA1125 in Long Covid-19. After previous AXA1125 data had shown effects on mitochondrial function, inflammation, and bioenergetics, the Phase 2a trial was designed to test AXA1125 in treating symptoms of fatigue and mental fatigue that follow COVID-19 infection.
Patients had improvements in their fatigue scores. The trial was a double-blind, placebo-controlled trial that enrolled 41 patients with Long COVID-19. Patients were randomized to receive either 67.8 grams per day of AXA1125 (n=21) or placebo (n=20) for 28 days. Trial endpoints included validated clinical fatigue measurements such as the Chalder Fatigue Questionnaire (CHQ-11), 6-minute walk test (6MWT), and other biomarkers….
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.